Ceftobiprole: The first anti-MRSA cephalosporin antibiotic

Formulary

Volumn 43, Issue 2, 2008, Pages 66-78

  Kontou, Paschalina ^a   Kuti, Joseph L ^b   Nicolau, David P ^b  

^a G Papanikolaou Hospital   (Greece)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; MACROLIDE; ORITAVANCIN; PENICILLIN G; PLACEBO; QUINOLONE DERIVATIVE; QUINUPRISTIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC FOOT; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ENTEROCOCCUS FAECALIS; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE COCCI; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA AND VOMITING; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 39749203496     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Appelbaum PC. MRSA - the tip of the iceberg. Clin Microbiol Infect. 2006;12(suppl 2):3-10.
2. Deresinski S. Methicillin-resistant Staphylococcus aureus: An evolutionary, epidemiologic, and therapeutic Odyssey. Clin Infect Dis. 2005;40: 562-573.
3. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; for the EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-674.
4. Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: The first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs. 2007;16:419-429.
5. Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004;48:2570-2575.
6. Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect. 2007;13(suppl 2):25-29.
7. Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004;48:2576-2580.
8. Schmitt-Hoffmann AH, Roos B, Heep M, et al. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of pro-drug BAL5788. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Abstract P1030.
9. Lodise TP Jr, Pypstra R, Kahn JB, et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother. 2007;51:2378-2387.
10. Laohavaleeson S, Tessier PR, Nicolau DP. Pharmacodynamic characterization of ceftobiprole in pneumonia caused by phenotypically diverse Staphylococcus aureus. Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract A-38.
11. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet. 2008; 47:21-33.
12. Lemaire S, Van Bambeke F, Glupczynski Y, Tulkens PM. Intraphagocytic activities of ceftobiprole vs conventional cephalosporins against methicillin-sensitive (MSSA) and methicillin-resistant S aureus (MRSA). Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract A-1438.
13. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 2005;49:4210-4219.
14. Kosowska K, Hoellman DB, Lin G, et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother. 2005;49:1932-1942.
15. Arias CA, Singh KV, Panesso D, Murray BE. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates. Antimicrob Agents Chemother. 2007; 51:2043-2047.
16. Bogdanovich T, Clark C, Ednie L, et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother. 2106;50:2150-2157.
17. Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MG, Then RL. Ih vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2001;45:825-836.
18. Leonard SN, Cheung CM, Rybak MJ. In vitro activity of ceftobiprole (CEF) against clinical isolates of hospital (HA) and community-acquired (CA) methicillin-resistant Staphylococcus aureus (MRSA). Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract E-278.
19. Denis O, Deplano A, Nonhoff C, et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother. 2006;50:2680-2685.
20. Deshpande LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect. 2003; 9:1120-1124.
21. Queenan AM, Shang W, Kania M, Page MGP, Bush K. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother. 2007;51:3089-3095.
22. Brown NP, Jones ME, Draghi DC, Cohen MA, Thornsberry C, Sahm DF. Baseline surveillance profiles of ceftobiprole (BPR) activity against Enterobacteriaceae and P aeruginosa (PA). Poster presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Poster E-112.
23. Fritsche TR, Sader HS, Jones RN. In vitro activity of ceftobiprole tested against a recent collection of North American Pseudomonas aeruginosa. Poster presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Poster E-115.
24. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother. 2006;50:3959-3962.
25. Heep M, Querner S, Harsch M, O'Riordan W. BAL5788, the first of a new class of anti-MRSA cephalosporins: Microbiological results from a phase II study in complicated skin and skin structure infections. Presented at: 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract L-361.
26. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52:37-44.
27. Strauss RS, Bagchi P, Noel GJ. Ceftobiprole (BPR) as treatment of complicated skin structure infections (cSSSI) caused by gram-negative infections, including Pseudomonas aeruginosa (PsA). Presented at: 45th Annual Meeting of the Infectious Diseases Society of America; October 4-7, 2007; San Diego, CA. Abstract 1094.
28. Strauss RS, Bagchi P, Noel GJ. Ceftobiprole (BPR) compared to vancomycin plus ceftazidime (VAN+CAZ) in treatment of diabetic patients with mild, moderate and severe foot infections. Presented at: 45th Annual Meeting of the Infectious Diseases Society of America; October 4-7, 2007; San Diego, CA. Abstract 1086.
29. Basilea announces positive top-line data from phase III study of ceftobiprole in community-acquired pneumonia requiring hospitalization [press release]. Basel, Switzerland: Basilea Pharmaceutica, Ltd; September 14, 2007. http://www.basilea.com/template_loader.php?tplpage_id=34&mode= details&id=131. Accessed January 17, 2008.
30. Basilea announces positive top-line data from phase III study of ceftobiproie in hospital-acquired pneumonia (press release]. Basel, Switzerland: Basilea Pharmaceutica, Ltd; October 9, 2007.http://www.basilea.com/ template_loader.php?tplpage_id=34&mode=details&id=144. Accessed January 17, 2008.